- Congressman: McAuliffe victory means gun control a winning message
- Clinton aide admits soliciting disgraced D.C. fundraiser; says actions were legal
- Joel Osteen church victimized in $600K theft
- Obama goes shopping at Gap as minimum-wage thanks
- N.J. woman charged after client dies from black-market butt injections
- CIA chief Brennan ‘determined’ to speak out more this year
- Reset? What reset? U.S.-Russia ties at worst since Cold War
- 9/11 terror recruiter released in Syrian prisoner swap
- D.C. elections board gives green light to marijuana legalization initiative
- Elephants can tell difference between human languages: study
Highly anticipated weight-loss pill wins approval
WASHINGTON — A new weight-loss pill that many doctors consider the most effective of a new generation of anti-obesity drugs got the approval of the Food and Drug Administration on Tuesday.
The pill, called Qsymia, was approved for patients who are overweight or obese and also have at least one weight-related condition such as high blood pressure, diabetes or high cholesterol.
The drug offers hope for those who have failed to lose weight in other ways, but its path to approval also underscores how difficult it has been for drugmakers to find obesity treatments that are safe and effective.
The drug’s maker, Vivus Inc., said it plans to bring the drug to market in the fourth quarter of this year. It hasn’t yet decided what the pills will cost.
In testing, the drug made led patients to lose more weight than two other weight-loss pills recently review by the FDA. Patients taking Qsymia for a year lost 6.7 percent of their body weight in one study and 8.9 percent in another study, the FDA said. The company said patients on the strongest formulation tested lost nearly 11 percent of their weight.
Despite its impressive performance in clinical trials, Qsymia is not exactly a scientific breakthrough. The drug is actually a combination of two older drugs long known to help with weight loss: phentermine and topirimate.
Phentermine is a stimulant that suppresses the appetite, and has long been used for short-term weight loss. Topiramate is an anticonvulsant, sold by Johnson & Johnson as Topamax, that makes people feel more satisfied after eating.
Researchers say the innovation of Qsymia lies in targeting more than one of the brain signals that drive people to overeat.
“We now know there are multiple pathways that determine how much energy we take in every day,” said Dr. Tim Garvey of the University of Alabama at Birmingham. “If you intervene on one pathway it’s hard to make much of a difference, you really need to attack multiple mechanisms to get a pronounced effect.”
Garvey helped conduct several pivotal trials of the drug.
Qsymia is the second weight-loss drug approved by the FDA in less than a month, following Arena Pharmaceutical’s pill Belviq in late June. Previously the agency had not approved a new drug for long-term weight loss since 1999.
With U.S. obesity rates nearing 35 percent of the adult population, many doctors have called on the FDA to approve new weight-loss treatments. But a long line of prescription diet pills have been associated with dangerous side effects, particularly heart problems.
In 1997, the popular diet drug combination fen-phen was linked to heart valve damage. The cocktail of phentermine and fenfluramine was a popular weight-loss combination prescribed by doctors, though it was never approved by the FDA. Fenfluramine was eventually withdrawn from the market.
Other safety failures for diet pills have continued to pile up in recent years. In 2010, Abbott Laboratories withdrew its drug Meridia after a study showed it increased risks for heart attack and stroke.
The FDA’s approvals of Qsymia and Belviq suggest a new willingness to make weight-loss medications available, even in the face of lingering safety issues.
TWT Video Picks
An America drowning in red ink is the land of the free no more
- David Jolly wins in Florida, GOP keeps swing district seat
- House Democrats trying to force unemployment insurance vote
- Kim Jong-un calls for execution of 33 Christians
- Redskins bypass big splash - for now - as free agency period begins
- U.S. pilot scares off Iranians with 'Top Gun'-worthy stunt: 'You really ought to go home'
- FCC targets black conservative in TV station fight
- Hillary Clinton campaign received funds from Jeffrey Thompson
- Bill Clinton poses for photo with Bunny Ranch prostitutes
- Senate Democrats, Republicans spar over restoring unemployment benefits
- Sharyl Attkisson resigns from CBS after months of talks
Pope Francis meets his 'mini-me'
Celebrity deaths in 2014
Winter storm hits states — again